TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and postmenopausal women aged ≥50 who have sustained a unilateral, fracture of the trochanteric region~* Lumbar spine BMD and/or femoral neck BMD and/or total hip BMD measurement of the contra lateral hip at least 2.0 SDs (standard deviation) below the average bone mass for young women and men~Exclusion Criteria:~* Clinically significant abnormal laboratory values~* History of unresolved skeletal diseases that affect bone metabolism~* Polytrauma participants and participants with fractures at more than one site

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): 20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only.
- Risedronate (Type: ACTIVE_COMPARATOR): 35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type Ⅱ diabetes mellitus~2. Non-alcoholic fatty liver disease: subjects who have CAP(Controlled Attenuation Parameter) ≥ 250dB/m measured by transient elastography (fibroscan) at screening test~3. Age ≥ 20 years~4. Patients who have not been taking any oral hypoglycemic agent for more than 12 weeks with HbA1c 7.0 to 8.5% at screening test or who have been taking metformin monotherapy for at least 8 weeks with HbA1c 7 to 9% at screening test~5. Agreement with written informed consent~Exclusion Criteria:~1. Patients whose alcohol consumption \>210g/week for males and 140g/week for females~2. chronic B viral hepatitis, chronic C viral hepatitis, Type I diabetes, or secondary diabetes~3. having a history of acute or chronic metabolic acidosis including diabetic ketoacidosis~4. patients who have been taking other oral hypoglycemic agents except metformin or insulin within recent 8 weeks~5. who experienced hypersensitivity reaction against metformin or glitazone drugs~6. who has been treated with corticosteroids for at least 14 days within 2 month prior to Screening~7. having a history of lactic acidosis~8. having genetic predispositions such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~9. who are in condition of malnutrition, starvation, cachexia, severe infection, major trauma, hypopituitarism, or adrenal insufficiency~10. diagnosed with cancer within 2 years or having chemo or radiotherapy for cancer treatment~11. a history of drug abuse or chronic alcoholism~12. a history of heart failure (NYHA class III and IV) or uncontrolled arrhythmia~13. a history of acute cardiovascular or cerebrovascular disease within 12 weeks prior to Screening (unstable angina, myocardial infarction, transient ischemic attack, cerebral infarct, cerebral hemorrhage, coronary bypass, percutaneous coronary intervention)~14. Renal dysfunction: Serum creatinine greater than 1.5mg/dl for males and 1.4mg/dl for females.~15. Anemia less than 10.5g/dl for any reason~16. Pregnant women or nursing mothers~17. Fertile women who not practice contraception with appropriate methods~18. in treatment concomitant drug from other clinical trials within 4 weeks from enrollment~19. who did not agree with written informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lobeglitazone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria for alcohol abuse or dependence~* Age 18 or older~* English speaking~* Smoking 1 or more cigarettes/day~* Male or female veterans eligible for VA healthcare~* Female nonveterans also eligible~Exclusion Criteria:~* Allergy or hypersensitivity to nicotine or adhesives used in nicotine patch~* Weigh less than 100 lbs~* Lack of interest in stopping smoking~* Pregnant or lactating females or females not practicing acceptable form of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 concurrent smoking cessation (Type: EXPERIMENTAL): smoking cessation delivered concurrent with intensive alcohol treatment
- 2 deferred smoking cessation (Type: ACTIVE_COMPARATOR): smoking cessation delivered 12 weeks after intensive alcohol treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintaining Autonomy as we Age. Strategy Training for Age-related Executive Dysfunction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All participants must score within 1.5 standard deviation (SD) of age and education-corrected normative data for the Montreal Cognitive Assessment and on a battery of neuropsychological tests of attention, memory and executive function (which will insure that participants are unlikely to meet the criteria for Mild Cognitive Impairment (MCI)).~* No clinically relevant depression (scores ≤22) on the Center for Epidemiologic Studies Depression Scale (CES-D)~* Fluent in written and spoken English~* Self-reported complains about cognitive function~Exclusion Criteria:~* Recent bereavement (within last 6 months)~* History of neurological disease~* Psychiatric illness requiring hospitalization and/or history or current substance abuse

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Cognitive Training (Type: EXPERIMENTAL): None
- Psychosocial Education (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 or older with chronic heart failure and evidence of diastolic dysfunction on echocardiogram, heart imaging, and a minimum exercise tolerance average time of 120 seconds on two treadmill tests within 2 weeks of enrollment~Exclusion Criteria:~* unstable cardiovascular disease within 4 weeks of screening, history of heart attack, cardiac by-pass surgery or percutaneous intervention, stent placement, within 3 months of screening or amyloidosis, hypertrophic obstructive or restrictive cardiomyopathy, or constrictive pericarditis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitaxsentan sodium (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 to \< 10 years~* Amblyopia associated with strabismus, anisometropia, or both~* No ocular cause apparent for reduced visual acuity~* Visual acuity 20/40 to 20/80 (71 to 54 letters inclusive) in amblyopic eye~* Visual acuity 20/40 or better (\>= 69 letters) in sound eye~* Interocular difference \>= 3 logMAR lines (\>= 15 letters)~* No amblyopia treatment other than spectacles in last 6 months~  \*Any treatment more than 6 months prior to enrollment is acceptable~* Currently wearing spectacles~* Appropriate spectacles have been worn for 16 weeks prior to enrollment or visual acuity documented to be stable~* No myopia \> -6.00 D spherical equivalent in either eye~* Cycloplegic refraction within 6 months prior to enrollment~* Ocular examination within 6 months prior to enrollment~Exclusion Criteria:~* Current vision therapy or orthoptics~* Ocular cause for reduced visual acuity~* Prior intraocular or refractive surgery~* Known skin reactions to patch or bandage adhesives

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Patching (Type: ACTIVE_COMPARATOR): 2 hours daily patching of the sound eye plus one hour near activities while patching
- Bangerter filters (Type: ACTIVE_COMPARATOR): Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine Augmentation in Obsessive-Compulsive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* suffering from OCD~* Y-BOCS score of 18 or greater~* taking a therapeutic dose of an anti-OCD medication specified in the protocol~Exclusion Criteria:~* diagnosed with a mental disorder other than OCD~* taking tiagabine or pregabalin~* having had a previous trial of memantine~* receiving therapy for OCD~* substance abuse in the last 6 months~* personality disorders sufficiently severe to interfere with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Memantine open label (Type: EXPERIMENTAL): All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratified Sequential Treatment for CD20-positive PTLD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTLD with or without EBV association, confirmed after biopsy or resection of tumor~* Measurable disease of \> 2 cm in diameter and/or bone marrow involvement~* Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or other or a combination of the organ transplantations mentioned~* Karnofsky scale \>50% or ECOG ≤ 3~* Reduction of immunosuppression with or without antiviral therapy~* A complete surgical extirpation of tumor was not performed~* A radiation therapy was not performed~* Effective contraception for women in childbearing age~* Patient's written informed consent and written consent for data collection~* Patients are \> 18 years (or ≥ 15 years with parental agreement )~Exclusion Criteria:~* Life expectancy less than 6 weeks~* Karnofsky-scale \<50% or ECOG ≥ 3~* Treatment with rituximab before~* Known allergic reactions against foreign proteins~* Concomitant diseases, which exclude the administration of therapy as outlined by the study protocol~* non-compensated heart failure~* Dilatative cardiomyopathy~* Myocardial infarction during the last 6 months~* Severe non-compensated hypertension~* Severe non-compensated diabetes mellitus~* Renal insufficiency (creatinine more than 3-fold of the upper normal value), not related to lymphoma~* Hepatic insufficiency with transaminase values greater than 3-fold of the normal values and/or bilirubin levels \>3.0 mg/dl, not related to lymphoma~* Clinical signs of cerebral dysfunction~* Women during the lactation period, pregnant or of childbearing potential not using a reliable contraceptive method~* Involvement of the central nervous system by the disease~* Severe psychiatric disease~* Known to be HIV positive~* Missing written informed consent of the patient

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
- B (Type: EXPERIMENTAL): All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Gardasil-9 and Cervarix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 9-10-year-old girls and boys~Exclusion Criteria:~* previously received an HPV vaccine~* immunosuppressed~* known allergy to a vaccine component

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Immunogenicity two doses of Gardasil-9 (Type: ACTIVE_COMPARATOR): Subjects will receive two doses of Gardasil-9
- Immunogenicity Cervarix and Gardasil-9 (Type: EXPERIMENTAL): Subjects will receive a dose Cervarix and a dose Gardasil-9

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3471851 in Participants With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of psoriasis for at least 6 months~* Have active psoriasis plaques according to study- specific criteria~* Be willing and able to undergo skin biopsies~Exclusion Criteria:~* Have received certain topical medications for psoriasis within 14 days prior to baseline~* Have received certain systemic medications for psoriasis within 4 weeks prior to baseline~* Have received LY3471851 previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.
- Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851 (Type: EXPERIMENTAL): Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
- Cohort 2 - 24 μg/kg LY3471851 (Type: EXPERIMENTAL): Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Planning the Next Steps: Using an Implementation Intention Approach to Increase Daily Walking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently working full time~* Not engaged in regular exercise~* 35 years of age or older~Exclusion Criteria:~* Not healthy enough to engage in a walking intervention

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control group (Type: EXPERIMENTAL): Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
- Implementation Intention Condition (Type: EXPERIMENTAL): Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, ambulatory, male and female volunteers between 16 to 45~* Scheduled to undergo surgical removal of 1 - 2 impacted third molars, one of which must be at least a partial mandibular bony impaction~* No use of any analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, any other pain reliever (Over The Counter or prescription), or herbal supplements within 5 days of surgery~* Have moderate to severe postoperative pain on the Categorical Pain Intensity Scale (a score of at least 2 on a 4 point scale) and a score of \>/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale~Exclusion Criteria:~* History of hypersensitivity to naproxen sodium, aspirin (ASA), other NSAIDs, opioid analgesics, and similar pharmacological agents or components of the investigational products, including the placebo~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies~* Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study~* Current or past history of bleeding disorder(s)~* History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Naproxen sodium ER (BAYH6689) (Type: EXPERIMENTAL): single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Chronic obstructive pulmonary disease (COPD) participants-~Inclusion criteria:~* Body Mass Index (BMI) \<36~* Moderate to severe COPD patient, (similar to or slightly better than Gold Guidelines Stage 2-3, forced expiratory volume in one second \[FEV_1\] \<60% of age predicted)~* Smoking history of 10 pack years or more~* Clinical diagnosis of COPD~* Not on daytime oxygen~Exclusion criteria:~* Clinical diagnosis of asthma~* Myocardial infarction within the last 6 months, or known ischemia~* Serious uncontrolled cardiac arrhythmia (i.e., atrial fibrillation or ventricular tachycardia) or hospitalization for heart failure within the previous year~* Known moderate to severe renal impairment~* Known moderate to severe symptomatic prostatic hypertrophy or bladder neck obstruction~* Known narrow angle glaucoma~* Current radiation or chemotherapy for a malignant condition~* Inability to give informed consent~* On systemic corticosteroids at unstable doses or on regular daily doses of 20 mg or more of prednisone (or equivalent)~* Not fully recovered from an exacerbation of COPD for at least 30 days~* Inability to perform light to moderate activity for orthopedic reasons or who significantly desaturated with exercise (percentage of available hemoglobin that is saturated with oxygen \[SaO_2\] \< 85% on screening test~Healthy controls -~Inclusion:~- Age and gender matched to COPD participants~Exclusion:~- Subjects who are unable to engage in exercise testing due to existing comorbidities

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Tiotropium (Type: EXPERIMENTAL): Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
- Placebo (Type: PLACEBO_COMPARATOR): Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
- Healthy Controls (Type: NO_INTERVENTION): Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete